Overview

Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy

Status:
Completed
Trial end date:
2016-04-13
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine if BVS857 is safe, tolerable and increases thigh muscle thickness in patients with spinal bulbar and muscular atrophy (SBMA).
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals